Five Prime files for IPO; Intrexon sets terms
This article was originally published in Scrip
Executive Summary
Five Prime Therapeutics intends to raise up to $60 million for two Phase I clinical trials and other expenses in an initial public offering as early-stage biotechnology companies increasingly take advantage of the open IPO window.